Urothelial Carcinoma
Information
- Disease name
- Urothelial Carcinoma
- Disease ID
- Description
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05243550 | Active, not recruiting | Phase 3 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | March 1, 2022 | February 2028 |
| NCT03988309 | Active, not recruiting | N/A | STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA | September 11, 2019 | December 2024 |
| NCT03917381 | Active, not recruiting | Phase 1/Phase 2 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | May 14, 2019 | October 2025 |
| NCT05200988 | Active, not recruiting | Phase 2 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC | March 14, 2022 | September 5, 2027 |
| NCT04943380 | Active, not recruiting | Efficacy and Utility of Cxbladder Tests in Hematuria Patients | November 8, 2019 | December 2025 | |
| NCT04902872 | Active, not recruiting | Phase 1/Phase 2 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | May 3, 2021 | September 2024 |
| NCT02845323 | Active, not recruiting | Phase 2 | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder | May 16, 2017 | December 2024 |
| NCT03898180 | Active, not recruiting | Phase 3 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | May 6, 2019 | July 1, 2024 |
| NCT02968732 | Active, not recruiting | N/A | Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder | November 11, 2016 | April 1, 2027 |
| NCT01261728 | Active, not recruiting | Phase 2 | Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | December 14, 2010 | December 2024 |
| NCT04344795 | Active, not recruiting | Phase 1 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | May 6, 2020 | October 1, 2024 |
| NCT04242199 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | September 4, 2020 | October 31, 2025 |
| NCT02989584 | Active, not recruiting | Phase 1/Phase 2 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | December 20, 2016 | December 2024 |
| NCT03871036 | Active, not recruiting | Phase 1/Phase 2 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | May 1, 2019 | January 31, 2025 |
| NCT04116320 | Active, not recruiting | Phase 1 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | November 21, 2019 | February 2024 |
| NCT04730219 | Active, not recruiting | Phase 2 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | July 11, 2020 | July 2024 |
| NCT05562830 | Active, not recruiting | Phase 1/Phase 2 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | November 16, 2022 | October 28, 2027 |
| NCT05242822 | Active, not recruiting | Phase 1 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | April 18, 2022 | September 2026 |
| NCT03782207 | Active, not recruiting | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | February 7, 2019 | July 31, 2026 | |
| NCT03039413 | Active, not recruiting | Early Phase 1 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | September 28, 2016 | April 2024 |
| NCT03752398 | Active, not recruiting | Phase 1 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | May 1, 2019 | September 2025 |
| NCT03575013 | Active, not recruiting | Phase 1 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | October 29, 2018 | February 23, 2026 |
| NCT03093922 | Active, not recruiting | Phase 2 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | March 22, 2017 | March 2025 |
| NCT03170960 | Active, not recruiting | Phase 1/Phase 2 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | September 5, 2017 | August 2024 |
| NCT04113603 | Active, not recruiting | N/A | Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography | June 1, 2019 | December 30, 2024 |
| NCT03179943 | Active, not recruiting | Phase 2 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | November 27, 2017 | July 2022 |
| NCT02365766 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | May 27, 2015 | July 1, 2024 |
| NCT03557918 | Active, not recruiting | Phase 2 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | November 12, 2018 | April 2023 |
| NCT03502785 | Active, not recruiting | Phase 1/Phase 2 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | May 24, 2018 | December 31, 2024 |
| NCT03473756 | Active, not recruiting | Phase 1 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma | May 15, 2018 | August 30, 2024 |
| NCT03473743 | Active, not recruiting | Phase 1/Phase 2 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | April 5, 2018 | June 30, 2025 |
| NCT03228667 | Active, not recruiting | Phase 2 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | December 11, 2018 | December 2024 |
| NCT04871594 | Active, not recruiting | Phase 1 | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer | August 23, 2021 | June 2, 2026 |
| NCT04018053 | Active, not recruiting | Early Phase 1 | 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy | February 26, 2020 | December 30, 2024 |
| NCT04822350 | Active, not recruiting | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | July 13, 2021 | June 30, 2024 | |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT04004442 | Active, not recruiting | Phase 1 | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma | February 17, 2020 | September 2024 |
| NCT02589717 | Approved for marketing | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | November 2015 | August 2016 | |
| NCT06443944 | Available | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG | |||
| NCT05494411 | Available | Named Patient Program for Mitomycin for Pyelocalyceal Solution | |||
| NCT00362713 | Completed | Phase 1 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | March 2007 | October 2009 |
| NCT00588666 | Completed | Phase 2 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | May 2006 | December 2011 |
| NCT01328574 | Completed | Phase 2 | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | March 2011 | November 2014 |
| NCT01437488 | Completed | Phase 2 | Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | February 16, 2012 | March 30, 2017 |
| NCT01490437 | Completed | Phase 2 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma | July 2008 | December 2013 |
| NCT01524991 | Completed | Phase 2 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | January 2012 | December 31, 2018 |
| NCT01600339 | Completed | Phase 2 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | May 2012 | January 2015 |
| NCT01606345 | Completed | Phase 1 | Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | July 2012 | April 2016 |
| NCT01688999 | Completed | Phase 2 | Cabozantinib for Advanced Urothelial Cancer | September 11, 2012 | September 14, 2020 |
| NCT01780545 | Completed | Phase 2 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | April 2013 | October 2017 |
| NCT01844947 | Completed | Phase 1 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | May 2012 | June 5, 2018 |
| NCT02236195 | Completed | Phase 2 | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | October 2014 | July 2016 |
| NCT02426125 | Completed | Phase 3 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | July 13, 2015 | July 26, 2022 |
| NCT02482168 | Completed | Phase 1 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | May 2015 | June 19, 2018 |
| NCT02500121 | Completed | Phase 2 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | November 11, 2015 | January 1, 2021 |
| NCT02573259 | Completed | Phase 1 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | February 10, 2016 | November 19, 2020 |
| NCT02585362 | Completed | N/A | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | March 2016 | October 2018 |
| NCT02643043 | Completed | N/A | UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | July 26, 2017 | September 13, 2023 |
| NCT02665039 | Completed | Phase 2 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | April 2014 | September 2018 |
| NCT02700659 | Completed | The Cxbladder Monitoring Study | February 4, 2013 | September 23, 2016 | |
| NCT02788201 | Completed | Phase 2 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | March 27, 2017 | October 23, 2019 |
| NCT02795156 | Completed | Phase 2 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | September 28, 2016 | August 17, 2022 |
| NCT02807636 | Completed | Phase 3 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | June 30, 2016 | February 12, 2024 |
| NCT02983045 | Completed | Phase 1/Phase 2 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | December 19, 2016 | April 28, 2022 |
| NCT02986867 | Completed | N/A | SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma | June 13, 2017 | March 7, 2018 |
| NCT02989064 | Completed | Phase 1 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | October 2016 | June 4, 2020 |
| NCT03013894 | Completed | Confocal Laser Endomicroscopy in the Lower Urinary Tract | March 2016 | October 2017 | |
| NCT03013920 | Completed | CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma | August 2016 | April 2018 | |
| NCT03171493 | Completed | Phase 1 | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | July 20, 2018 | May 12, 2023 |
| NCT03190174 | Completed | Phase 1/Phase 2 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | August 24, 2017 | December 2, 2021 |
| NCT03232593 | Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | November 29, 2017 | August 12, 2022 | |
| NCT03240016 | Completed | Phase 2 | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer | February 8, 2018 | June 23, 2023 |
| NCT03330886 | Completed | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | February 9, 2018 | March 2, 2019 | |
| NCT03387761 | Completed | Phase 1 | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | January 15, 2018 | September 13, 2021 |
| NCT03507166 | Completed | Phase 2 | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | December 28, 2017 | October 29, 2018 |
| NCT03511391 | Completed | Phase 2 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | March 9, 2018 | January 23, 2024 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03520231 | Completed | Phase 2 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | September 4, 2018 | December 1, 2020 |
| NCT03538028 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | June 18, 2018 | October 7, 2020 |
| NCT03548688 | Completed | Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: | December 14, 2017 | January 1, 2020 | |
| NCT03558503 | Completed | Phase 2 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | October 15, 2018 | October 21, 2020 |
| NCT03582475 | Completed | Phase 1 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | December 20, 2018 | May 16, 2022 |
| NCT03584659 | Completed | N/A | Patient-reported Outcomes in Bladder Cancer | January 21, 2019 | March 31, 2022 |
| NCT03633110 | Completed | Phase 1/Phase 2 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | August 29, 2018 | February 28, 2022 |
| NCT03636256 | Completed | Phase 1/Phase 2 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | April 2, 2019 | November 2, 2021 |
| NCT03639714 | Completed | Phase 1/Phase 2 | A Study of a Personalized Neoantigen Cancer Vaccine | February 13, 2019 | November 10, 2022 |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT03658304 | Completed | Phase 2 | Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | December 5, 2018 | December 14, 2023 |
| NCT03665285 | Completed | Phase 1/Phase 2 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | October 1, 2018 | April 11, 2023 |
| NCT03677544 | Completed | Predictive Factorsfor Final Pathologic Ureteral Sections | January 1, 2016 | June 1, 2017 | |
| NCT03689192 | Completed | Phase 1 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | December 17, 2018 | January 19, 2022 |
| NCT03735680 | Completed | Phase 2 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | August 9, 2019 | November 18, 2021 |
| NCT03758781 | Completed | Phase 1 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | February 13, 2019 | August 11, 2021 |
| NCT03788746 | Completed | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma | January 17, 2019 | May 25, 2023 | |
| NCT03794102 | Completed | N/A | Water Versus Saline as Irrigation Fluid for Ureteroscopy | January 17, 2017 | June 30, 2018 |
| NCT03794128 | Completed | A Study of Personalized Neoantigen Cancer Vaccines | July 25, 2018 | May 26, 2020 | |
| NCT03809013 | Completed | Phase 2 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | January 7, 2019 | June 5, 2023 |
| NCT03829436 | Completed | Phase 1 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | March 20, 2019 | September 7, 2022 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT03894618 | Completed | Phase 1 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | March 26, 2019 | May 4, 2023 |
| NCT03945084 | Completed | Phase 2 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy | August 27, 2019 | September 1, 2021 |
| NCT03980041 | Completed | Phase 2 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | September 25, 2019 | November 15, 2022 |
| NCT04045613 | Completed | Phase 1/Phase 2 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer | August 2, 2019 | October 4, 2022 |
| NCT04073602 | Completed | Phase 2 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | August 19, 2019 | January 31, 2023 |
| NCT04077359 | Completed | N/A | Prospective Trial for Examining Hematuria Using Computed Tomography | September 15, 2019 | July 1, 2021 |
| NCT04197089 | Completed | Phase 4 | Biological Effect of Vitamin D in Patients With Urothelial Carcinoma | February 11, 2020 | November 22, 2021 |
| NCT04200963 | Completed | Phase 1 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | December 18, 2019 | July 18, 2023 |
| NCT04314245 | Completed | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | August 1, 2019 | August 31, 2022 | |
| NCT04322643 | Completed | Phase 2 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | March 23, 2020 | April 17, 2023 |
| NCT04383938 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | June 25, 2020 | April 30, 2022 |
| NCT04452214 | Completed | Phase 1 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | September 24, 2020 | June 28, 2023 |
| NCT04535921 | Completed | Fear of Cancer Recurrence in Genitourinary Cancer | November 5, 2019 | August 31, 2022 | |
| NCT04601402 | Completed | Phase 1 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | October 26, 2020 | January 11, 2023 |
| NCT05046665 | Completed | Phase 1 | Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients | May 14, 2021 | August 9, 2022 |
| NCT05070039 | Completed | N/A | Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population | July 1, 2021 | January 1, 2022 |
| NCT05136898 | Completed | Phase 3 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | November 30, 2021 | February 2, 2023 |
| NCT05431777 | Completed | A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread | July 19, 2022 | January 16, 2023 | |
| NCT06169904 | Completed | B7-Family Score in Urothelial Carcinoma | January 25, 2012 | November 22, 2022 | |
| NCT06193941 | Completed | Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits | June 1, 2023 | December 1, 2023 | |
| NCT06427993 | Not yet recruiting | Urine DNA Methylation Detection for Hematuria Evaluation | June 15, 2024 | December 31, 2025 | |
| NCT05912205 | Not yet recruiting | Phase 2 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | July 1, 2023 | July 1, 2026 |
| NCT06262516 | Not yet recruiting | N/A | Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma | July 1, 2024 | January 1, 2029 |
| NCT06356155 | Not yet recruiting | Phase 2 | Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer | October 2024 | July 2027 |
| NCT05893316 | Not yet recruiting | UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study | June 1, 2023 | February 1, 2024 | |
| NCT06332755 | Not yet recruiting | Phase 1 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors | May 2024 | February 2027 |
| NCT06396533 | Not yet recruiting | Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) | May 2024 | February 23, 2029 | |
| NCT05030077 | Not yet recruiting | Phase 2 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | October 1, 2021 | September 1, 2024 |
| NCT06113367 | Not yet recruiting | Immunotherapy in Upper Tract Urothelial Carcinoma | November 1, 2023 | February 28, 2024 | |
| NCT06421311 | Not yet recruiting | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France | June 15, 2024 | May 1, 2028 | |
| NCT06318871 | Not yet recruiting | Early Phase 1 | Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | June 2024 | February 28, 2030 |
| NCT06424717 | Not yet recruiting | Phase 2 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | July 29, 2024 | January 27, 2026 |
| NCT06405425 | Not yet recruiting | Phase 2 | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | May 2024 | May 2026 |
| NCT06221774 | Not yet recruiting | Phase 1/Phase 2 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | February 1, 2024 | November 30, 2025 |
| NCT06331299 | Not yet recruiting | Phase 3 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | July 2024 | March 2026 |
| NCT05585034 | Recruiting | Phase 1 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | December 14, 2022 | December 2027 |
| NCT05600127 | Recruiting | Phase 2 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer | December 1, 2022 | December 2026 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT05646485 | Recruiting | N/A | Bladder Cancer Screening Trial | May 5, 2023 | April 2028 |
| NCT05661955 | Recruiting | Phase 1/Phase 2 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | January 19, 2023 | August 2025 |
| NCT05683418 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | February 15, 2023 | December 2025 |
| NCT05714553 | Recruiting | Phase 1/Phase 2 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | March 8, 2023 | January 2025 |
| NCT05723991 | Recruiting | Phase 4 | Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma | September 28, 2022 | September 28, 2025 |
| NCT05768347 | Recruiting | Phase 1 | Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | August 10, 2023 | November 2025 |
| NCT05775874 | Recruiting | Phase 2 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | September 30, 2022 | December 30, 2025 |
| NCT05823246 | Recruiting | Phase 2 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | April 24, 2023 | July 2024 |
| NCT06321640 | Recruiting | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. | July 8, 2022 | December 31, 2025 | |
| NCT06111235 | Recruiting | Phase 3 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | December 14, 2023 | January 2030 |
| NCT04140526 | Recruiting | Phase 1/Phase 2 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | September 16, 2020 | December 31, 2027 |
| NCT04146064 | Recruiting | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | February 24, 2020 | May 2024 | |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT03869190 | Recruiting | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | June 1, 2019 | November 27, 2027 |
| NCT02994758 | Recruiting | N/A | Development of Diagnostics and Treatment of Urological Cancers | November 27, 2017 | December 2025 |
| NCT04198766 | Recruiting | Phase 1 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | December 10, 2019 | May 15, 2026 |
| NCT06101290 | Recruiting | N/A | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) | October 5, 2023 | January 5, 2031 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06034860 | Recruiting | Phase 1 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | November 1, 2023 | October 2026 |
| NCT06265285 | Recruiting | Phase 2 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | March 13, 2024 | December 31, 2026 |
| NCT04260802 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | October 6, 2020 | September 30, 2026 |
| NCT06026189 | Recruiting | N/A | Safely Reduce Cystoscopic Evaluations for Hematuria Patients | May 31, 2023 | May 31, 2027 |
| NCT06022757 | Recruiting | Phase 1/Phase 2 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | September 20, 2023 | August 2028 |
| NCT06337084 | Recruiting | Phase 1 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | April 10, 2024 | June 2025 |
| NCT06339138 | Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | February 20, 2018 | January 31, 2027 | |
| NCT06171789 | Recruiting | Phase 1/Phase 2 | PRO1107 in Patients With Advanced Solid Tumors | January 29, 2024 | February 2027 |
| NCT05965856 | Recruiting | Phase 2 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | December 11, 2023 | December 2025 |
| NCT05945108 | Recruiting | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER | July 10, 2023 | July 30, 2024 | |
| NCT04459273 | Recruiting | Phase 1 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | August 27, 2020 | July 1, 2025 |
| NCT04510129 | Recruiting | A Multicenter Cancer Biospecimen Collection Study | February 5, 2020 | February 2027 | |
| NCT05923190 | Recruiting | Phase 2 | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | June 14, 2023 | July 1, 2029 |
| NCT04565275 | Recruiting | Phase 1/Phase 2 | A Study of ICP-192 in Patients With Advanced Solid Tumors | February 1, 2021 | April 15, 2024 |
| NCT06178601 | Recruiting | Phase 2 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | August 3, 2023 | April 1, 2026 |
| NCT02769962 | Recruiting | Phase 1/Phase 2 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | May 9, 2016 | December 31, 2027 |
| NCT03924466 | Recruiting | Phase 2 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | April 1, 2019 | December 2024 |
| NCT06412848 | Recruiting | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | May 9, 2024 | July 31, 2024 | |
| NCT04617756 | Recruiting | Phase 2 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract | September 29, 2021 | October 1, 2026 |
| NCT04623502 | Recruiting | N/A | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | September 30, 2019 | September 30, 2026 |
| NCT06285097 | Recruiting | Phase 1 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | February 8, 2024 | April 29, 2028 |
| NCT04666688 | Recruiting | Phase 1/Phase 2 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | December 15, 2020 | January 2025 |
| NCT04678362 | Recruiting | Phase 2 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma | June 1, 2021 | December 2023 |
| NCT03967977 | Recruiting | Phase 3 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | May 29, 2019 | June 2027 |
| NCT05911295 | Recruiting | Phase 3 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | September 22, 2023 | April 30, 2029 |
| NCT05902494 | Recruiting | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study | June 29, 2023 | July 31, 2024 | |
| NCT04773951 | Recruiting | Phase 1 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | April 12, 2021 | August 31, 2024 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT03475953 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | May 4, 2018 | December 31, 2025 |
| NCT06293898 | Recruiting | Phase 1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | February 9, 2024 | August 24, 2027 |
| NCT04879329 | Recruiting | Phase 2 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | May 3, 2022 | March 31, 2026 |
| NCT02717156 | Recruiting | Phase 2 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | November 21, 2016 | November 21, 2026 |
| NCT04892849 | Recruiting | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy | April 30, 2021 | December 31, 2027 | |
| NCT04895709 | Recruiting | Phase 1/Phase 2 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | May 27, 2021 | September 15, 2026 |
| NCT06451497 | Recruiting | Phase 1 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | May 22, 2024 | April 2027 |
| NCT06120413 | Recruiting | 18F-LN1 PET/CT in Urothelial Carcinomas | November 1, 2023 | October 2024 | |
| NCT06120374 | Recruiting | Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC | October 30, 2023 | October 30, 2028 | |
| NCT04970472 | Recruiting | Bio Clinical Collection of Urothelial Carcinoma | November 16, 2021 | July 14, 2031 | |
| NCT04994197 | Recruiting | Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS | April 1, 2022 | August 2024 | |
| NCT03212404 | Recruiting | Phase 1 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | September 20, 2017 | December 2024 |
| NCT06138561 | Recruiting | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | March 5, 2024 | March 1, 2026 | |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT05098132 | Recruiting | Phase 1 | Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors | January 25, 2022 | October 2025 |
| NCT05889195 | Recruiting | Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria | November 2, 2023 | May 2024 | |
| NCT05137262 | Recruiting | Phase 2 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | October 13, 2021 | August 31, 2026 |
| NCT05176483 | Recruiting | Phase 1 | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors | December 14, 2021 | May 2026 |
| NCT05180799 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | August 3, 2022 | June 30, 2025 |
| NCT06310759 | Recruiting | Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer | January 8, 2024 | December 31, 2029 | |
| NCT06116396 | Recruiting | Liquid Biospy for Urinary Cancers | September 29, 2020 | September 29, 2028 | |
| NCT03374267 | Recruiting | Registry Platform Urologic Cancer | December 7, 2017 | June 2027 | |
| NCT05229614 | Recruiting | Phase 2 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease | July 26, 2022 | August 2026 |
| NCT05874921 | Recruiting | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | November 17, 2023 | January 2028 | |
| NCT05239624 | Recruiting | Phase 2 | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | June 2, 2022 | June 2025 |
| NCT03317158 | Recruiting | Phase 1/Phase 2 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | November 21, 2017 | December 31, 2025 |
| NCT06218433 | Recruiting | N/A | Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study) | April 10, 2023 | December 31, 2034 |
| NCT05290038 | Recruiting | ARON-2 Study-Multicentric International Retrospective Study | February 17, 2022 | January 31, 2024 | |
| NCT05302284 | Recruiting | Phase 3 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | June 14, 2022 | April 30, 2028 |
| NCT05335941 | Recruiting | Phase 2 | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | June 13, 2023 | September 30, 2025 |
| NCT05321316 | Recruiting | N/A | Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma | May 31, 2022 | December 2024 |
| NCT05337189 | Recruiting | A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China | March 9, 2022 | July 30, 2024 | |
| NCT05406713 | Recruiting | Phase 2 | Pembrolizumab in Muscle-invasive Bladder Cancer | July 13, 2022 | June 2024 |
| NCT06438588 | Recruiting | N/A | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial | March 6, 2024 | March 15, 2027 |
| NCT03291028 | Recruiting | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | November 27, 2017 | December 2024 | |
| NCT05868265 | Recruiting | Phase 2 | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | June 2, 2023 | May 2025 |
| NCT05520099 | Recruiting | Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | June 26, 2023 | January 2027 | |
| NCT05522257 | Recruiting | N/A | PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas | August 1, 2022 | June 1, 2024 |
| NCT05524545 | Recruiting | Phase 1 | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | November 2, 2022 | April 2025 |
| NCT05544552 | Recruiting | Phase 1/Phase 2 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | November 22, 2022 | June 2027 |
| NCT05548296 | Recruiting | Phase 1/Phase 2 | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | August 29, 2022 | December 31, 2027 |
| NCT05867303 | Recruiting | Phase 1 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | June 5, 2023 | September 30, 2024 |
| NCT05861947 | Recruiting | Phase 1 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies | August 26, 2023 | June 2025 |
| NCT05574504 | Recruiting | Phase 2 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | May 8, 2023 | November 2028 |
| NCT05581004 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | October 20, 2022 | October 31, 2025 |
| NCT00565227 | Terminated | Phase 1 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | April 2007 | September 2009 |
| NCT02887248 | Terminated | Phase 2 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | January 12, 2017 | May 1, 2020 |
| NCT03915405 | Terminated | Phase 1 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | September 26, 2019 | November 15, 2022 |
| NCT03992131 | Terminated | Phase 1/Phase 2 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | June 28, 2019 | April 22, 2022 |
| NCT02479178 | Terminated | Phase 2 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck | June 2015 | January 2020 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT04066595 | Terminated | Phase 2 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. | February 10, 2020 | July 1, 2021 |
| NCT04106167 | Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | June 11, 2019 | August 11, 2023 | |
| NCT04173338 | Terminated | Phase 1 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | January 23, 2020 | March 28, 2022 |
| NCT04187872 | Terminated | Phase 1 | LITT and Pembrolizumab in Recurrent Brain Metastasis | January 10, 2020 | December 1, 2023 |
| NCT04244552 | Terminated | Phase 1 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | February 11, 2020 | November 1, 2023 |
| NCT04341740 | Terminated | N/A | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma | July 22, 2020 | April 9, 2021 |
| NCT04579133 | Terminated | Phase 2 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | March 1, 2021 | March 1, 2021 |
| NCT04586244 | Terminated | Phase 2 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | January 14, 2022 | January 29, 2024 |
| NCT04596033 | Terminated | Phase 1 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | November 11, 2020 | June 27, 2022 |
| NCT04628780 | Terminated | Phase 1 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | December 16, 2020 | May 26, 2023 |
| NCT04688931 | Terminated | Phase 3 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | February 19, 2021 | March 17, 2023 |
| NCT01353222 | Terminated | Phase 2 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | June 2011 | July 2015 |
| NCT04887831 | Terminated | Phase 2 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab | June 4, 2021 | March 1, 2024 |
| NCT01234519 | Terminated | Phase 1/Phase 2 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | November 2010 | November 2014 |
| NCT01215136 | Terminated | Phase 2 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 2010 | April 24, 2018 |
| NCT04960956 | Terminated | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | October 13, 2016 | February 2, 2017 | |
| NCT05052372 | Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | November 21, 2021 | December 20, 2022 | |
| NCT01093066 | Terminated | Phase 2 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy | September 21, 2010 | December 31, 2020 |
| NCT05219578 | Terminated | Phase 1/Phase 2 | RTX-224 Monotherapy in Patients With Solid Tumors | January 12, 2022 | November 30, 2022 |
| NCT01042795 | Terminated | Phase 2 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | September 2009 | January 2013 |
| NCT05699135 | Terminated | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer | March 9, 2023 | June 30, 2023 | |
| NCT03265080 | Terminated | Phase 1 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens | March 28, 2018 | November 12, 2020 |
| NCT03272217 | Terminated | Phase 2 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | September 13, 2017 | March 17, 2022 |
| NCT03287050 | Terminated | Phase 2 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | January 24, 2018 | November 10, 2020 |
| NCT03311334 | Terminated | Phase 1/Phase 2 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | December 14, 2017 | November 29, 2022 |
| NCT03397394 | Terminated | Phase 2 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | June 1, 2018 | January 15, 2020 |
| NCT03399643 | Terminated | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) | December 28, 2017 | January 28, 2019 | |
| NCT03407976 | Terminated | Phase 1 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | June 19, 2018 | July 2, 2020 |
| NCT03486197 | Terminated | Phase 2 | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | January 17, 2019 | May 1, 2024 |
| NCT03208712 | Terminated | Early Phase 1 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | November 1, 2017 | August 2, 2018 |
| NCT03606174 | Terminated | Phase 2 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | September 11, 2018 | August 22, 2022 |
| NCT03737123 | Terminated | Phase 2 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 19, 2018 | May 18, 2022 |
| NCT03029832 | Terminated | Phase 2 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | April 27, 2017 | April 25, 2018 |
| NCT05226117 | Unknown status | Phase 2 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | November 29, 2021 | June 2023 |
| NCT03676946 | Unknown status | Phase 1/Phase 2 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | October 10, 2018 | June 23, 2023 |
| NCT04047693 | Unknown status | Phase 2 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | May 1, 2019 | October 31, 2022 |
| NCT02535650 | Unknown status | Phase 2 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | November 12, 2015 | June 2022 |
| NCT05086666 | Unknown status | Phase 1/Phase 2 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | June 3, 2021 | May 27, 2024 |
| NCT05043662 | Unknown status | UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. | September 1, 2021 | December 30, 2022 | |
| NCT03209206 | Unknown status | Phase 2 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | June 28, 2017 | April 1, 2022 |
| NCT01360723 | Unknown status | DNA Methylation and Arsenic-associated Urothelial Carcinoma | May 2011 | ||
| NCT03998371 | Unknown status | Application of UCAD for Diagnosing Urothelial Carcinoma. | May 5, 2019 | May 5, 2020 | |
| NCT03827837 | Unknown status | Phase 2 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | January 23, 2019 | December 2022 |
| NCT04770974 | Unknown status | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | December 10, 2020 | December 7, 2022 | |
| NCT04295967 | Unknown status | Vasculogenic Mimicry in Urothelial Carcinoma | May 2020 | May 2022 | |
| NCT03062059 | Unknown status | Phase 2 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | March 1, 2018 | December 31, 2022 |
| NCT04264936 | Unknown status | Phase 1/Phase 2 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | February 15, 2020 | December 31, 2021 |
| NCT01993966 | Unknown status | EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells | January 2014 | December 2016 | |
| NCT00854464 | Unknown status | Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma | August 2008 | ||
| NCT04223063 | Unknown status | N/A | Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study | March 2020 | March 2022 |
| NCT04211012 | Unknown status | Phase 2 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | November 30, 2020 | January 30, 2023 |
| NCT03280459 | Unknown status | Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction | January 1, 2015 | June 1, 2023 | |
| NCT00867633 | Unknown status | Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan | March 2009 | March 2012 | |
| NCT02278978 | Unknown status | Phase 2 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | October 2014 | March 2016 |
| NCT01378052 | Unknown status | DNA Methylation and Urothelial Carcinoma | June 2011 | ||
| NCT04718948 | Unknown status | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | January 28, 2021 | January 25, 2024 | |
| NCT03523572 | Unknown status | Phase 1 | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | June 20, 2018 | July 2022 |
| NCT04566029 | Unknown status | Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas | December 2, 2020 | June 1, 2023 | |
| NCT04553939 | Unknown status | Phase 2 | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | January 4, 2021 | December 2023 |
| NCT04432909 | Unknown status | A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up | January 17, 2020 | June 30, 2022 | |
| NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
| NCT03577132 | Unknown status | N/A | The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer | August 1, 2018 | May 31, 2022 |
| NCT05894447 | Withdrawn | Phase 1 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | November 2023 | June 2028 |
| NCT02232646 | Withdrawn | Phase 2 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | January 2017 | August 1, 2018 |
| NCT03517995 | Withdrawn | Phase 2 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | April 2020 | December 2022 |
| NCT01907308 | Withdrawn | Phase 2 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | February 2014 | April 2014 |
| NCT05496192 | Withdrawn | Phase 2 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | May 31, 2023 | June 24, 2026 |
| NCT05234606 | Withdrawn | Phase 1/Phase 2 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | March 2022 | March 31, 2022 |
| NCT05107427 | Withdrawn | Phase 2 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma | March 1, 2022 | April 2023 |
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT01071928 | Withdrawn | Phase 2 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | June 2010 | June 2010 |
| NCT05564416 | Withdrawn | Phase 2 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | October 12, 2023 | November 3, 2023 |